Long-term Oncologic Outcomes of Radiotherapy Combined with Maximal Androgen Blockade for Localized, High-risk Prostate Cancer

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2018 Jun 13

PMID 29890979

Citations 1

Authors

Yong Luo

Mingchuan Li

Hengzhi Qi

Jiahui Zhao

Yili Han

Yunhua Lin

Zhu Hou

Yongguang Jiang

Affiliations

Soon will be listed here.

Abstract

Background: To assess the oncologic outcomes of radiation therapy (RT) combined with maximal androgen blockade (MAB) and prostate-specific antigen (PSA) kinetics in patients with localized, high-risk prostate carcinoma (PCa).

Methods: Three-hundred twenty individuals with localized PCa who underwent RT + MAB in 2001-2015 were evaluated retrospectively. All patients had received 36 months of MAB therapy and 45 Gy of pelvic irradiation, plus a dose-escalated external beam radiation therapy (DE-EBRT) boost to 76~81 Gy (MAB + EBRT group), or a low-dose-rate prostate permanent brachytherapy (LDR-PPB) boost to 110 Gy with I-125 (MAB + EBRT + PPB group).

Results: Follow-up median is 90 months, ranging from 12 to 186 months; 117 (36.6%) and 203 (63.4%) cases underwent MAB + EBRT and MAB + EBRT + PPB, respectively. Multivariate Cox regression showed that the PPB regimen and PSA kinetics were positive indicators of oncologic outcomes. Compared with MAB + EBRT, MAB + EBRT + PPB remarkably improved PSA kinetics more pronouncedly: PSA nadir (1.3 ± 0.7 vs 0.11 ± 0.06 ng/mL); time of PSA decrease to nadir (7.5 ± 1.8 vs 3.2 ± 2.1 months); PSA doubling time (PSADT; 15.6 ± 4.2 vs 22.6 ± 6.1 months); decrease in PSA (84.6 ± 6.2% vs 95.8 ± 3.4%). Additionally, median times of several important oncologic events were prolonged in the MAB + EBRT + PPB group compared with the MAB + EBRT group: overall survival (OS; 12.3 vs 9.1 years, P < 0.001), biochemical recurrence-free survival (BRFS; 9.8 vs 6.5 years, P < 0.001), skeletal-related event (SRE; 10.4 vs 8.2 years, P < 0.001), and cytotoxic chemotherapy (CCT; 11.6 vs 8.8 years, P = 0.007).

Conclusion: MAB + EBRT + PPB is extremely effective in patients with localized, high-risk PCa, indicating that PPB may play a synergistic role in improving PSA kinetics and independently predicts oncologic outcomes.

Citing Articles

Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions.

Wei S, Li C, Li M, Xiong Y, Jiang Y, Sun H Front Oncol. 2021; 11:717180.

PMID: 34660280 PMC: 8514864. DOI: 10.3389/fonc.2021.717180.

References

Davis B, Horwitz E, Lee W, Crook J, Stock R, Merrick G . American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012; 11(1):6-19. DOI: 10.1016/j.brachy.2011.07.005. View

Prada P, Gonzalez H, Fernandez J, Jimenez I, Iglesias A, Romo I . Biochemical outcome after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience. BJU Int. 2011; 109(12):1787-93. DOI: 10.1111/j.1464-410X.2011.10632.x. View

Taira A, Merrick G, Galbreath R, Butler W, Lief J, Adamovich E . Long-term outcomes of prostate cancer patients with Gleason pattern 5 treated with combined brachytherapy and external beam radiotherapy. Brachytherapy. 2013; 12(5):408-14. DOI: 10.1016/j.brachy.2012.08.004. View

Makino T, Mizokami A, Namiki M . Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute. Anticancer Res. 2015; 35(3):1723-8. View

Sylvester J, Grimm P, Wong J, Galbreath R, Merrick G, Blasko J . Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys. 2010; 81(2):376-81. DOI: 10.1016/j.ijrobp.2010.05.042. View

Tsumura H, Satoh T, Ishiyama H, Tabata K, Komori S, Sekiguchi A . Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer. J Contemp Brachytherapy. 2016; 8(2):95-103. PMC: 4873555. DOI: 10.5114/jcb.2016.59686. View

Crook J, Choan E, Perry G, Robertson S, Esche B . Serum prostate-specific antigen profile following radiotherapy for prostate cancer: implications for patterns of failure and definition of cure. Urology. 1998; 51(4):566-72. DOI: 10.1016/s0090-4295(97)00650-x. View

Ecke T, Huang-Tiel H, Golka K, Selinski S, Geis B, Koswig S . Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate.... Int J Mol Sci. 2016; 17(11). PMC: 5133879. DOI: 10.3390/ijms17111879. View

Scher H, Halabi S, Tannock I, Morris M, Sternberg C, Carducci M . Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26(7):1148-59. PMC: 4010133. DOI: 10.1200/JCO.2007.12.4487. View

10.

Sharkey J, Cantor A, Solc Z, Huff W, Chovnick S, Behar R . 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. Brachytherapy. 2005; 4(1):34-44. DOI: 10.1016/j.brachy.2004.12.001. View

11.

Skowronek J . Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options. J Contemp Brachytherapy. 2013; 5(1):33-41. PMC: 3635047. DOI: 10.5114/jcb.2013.34342. View

12.

Pound C, Partin A, Eisenberger M, Chan D, Pearson J, Walsh P . Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281(17):1591-7. DOI: 10.1001/jama.281.17.1591. View

13.

Polascik T, Pound C, DeWeese T, Walsh P . Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. Urology. 1998; 51(6):884-9; discussion 889-90. View

14.

Stewart A, Scher H, Chen M, McLeod D, Carroll P, Moul J . Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol. 2005; 23(27):6556-60. DOI: 10.1200/JCO.2005.20.966. View

15.

RAGDE H, Blasko J, Grimm P, Kenny G, Sylvester J, Hoak D . Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 1997; 80(3):442-53. DOI: 10.1002/(sici)1097-0142(19970801)80:3<442::aid-cncr12>3.0.co;2-x. View

16.

Morris W, Tyldesley S, Rodda S, Halperin R, Pai H, Mckenzie M . Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam.... Int J Radiat Oncol Biol Phys. 2017; 98(2):275-285. DOI: 10.1016/j.ijrobp.2016.11.026. View

17.

Zelefsky M, Reuter V, Fuks Z, Scardino P, Shippy A . Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol. 2008; 179(4):1368-73. PMC: 2646887. DOI: 10.1016/j.juro.2007.11.063. View

18.

Antonarakis E, Zahurak M, Lin J, Keizman D, Carducci M, Eisenberger M . Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials. Cancer. 2011; 118(6):1533-42. PMC: 3252493. DOI: 10.1002/cncr.26437. View

19.

DAmico A, Chen M, Roehl K, Catalona W . Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol. 2005; 23(22):4975-9. DOI: 10.1200/JCO.2005.08.904. View

20.

Jani A, Feinstein J, Pasciak R, Krengel S, Weichselbaum R . Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer. Urology. 2006; 67(5):1007-11. DOI: 10.1016/j.urology.2005.11.008. View